Publication:
Plasmapheresis as treatment for hyperlipidemic pancreatitis.

dc.contributor.authorRamírez-Bueno, A
dc.contributor.authorSalazar-Ramírez, C
dc.contributor.authorCota-Delgado, F
dc.contributor.authorTorre-Prados, M V de la
dc.contributor.authorValdivielso, P
dc.contributor.authoraffiliation[Ramírez-Bueno,A; Valdivielso,P] Unidad de Gestión Clínica de Medicina Interna, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Salazar-Ramírez,C; Cota-Delgado,F; Torre-Prados,M V de la] Unidad de Gestión Clínica de Cuidados Críticos y Urgencias, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Valdivielso,P] Unidad de Gestión Clínica de Cuidados Críticos y Urgencias, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Spain.
dc.date.accessioned2024-01-15T18:17:05Z
dc.date.available2024-01-15T18:17:05Z
dc.date.issued2014-02
dc.description.abstractBACKGROUND: Severe hypertriglyceridemia with an accumulation of chylomicrons and triglyceride figures >1000 mg/dL can cause acute pancreatitis, a potentially fatal complication. The option of rapid reduction in triglyceride concentrations is attractive and possible with plasmapheresis. METHODS: We present the results of an analysis of 11 patients admitted to the intensive care unit with severe hypertriglyceridemic pancreatitis and treated with plasmapheresis. The procedure was repeated until serum triglycerides were below 1000 mg/dL. We recorded anthropometric, clinical data as well as final outcome. RESULTS: In eight patients a single plasma exchange was sufficient to reduce triglyceride figures <1000 mg/dL. Only three patients died, all with the worst severity indexes and who experienced the longest delay before the procedure. CONCLUSIONS: Our results, together with a review of the literature, confirm the need for a randomized clinical trial to compare conventional treatment vs. plasmapheresis in patients with severe hypertriglyceridemic pancreatitis.
dc.description.sponsorshipThis study was partly financed by a grant from PAIDI (Plan Andaluz de Investigación, Desarrollo e Innovación) 159
dc.identifier.doi10.1016/j.ejim.2013.08.701
dc.identifier.e-issn1879-0828es_ES
dc.identifier.issn0953-6205
dc.identifier.journalEuropean journal of internal medicinees_ES
dc.identifier.otherhttp://hdl.handle.net/10668/1874
dc.identifier.pubmedID24012324es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17057
dc.language.isoeng
dc.publisherElsevier
dc.relation.publisherversionhttp://www.sciencedirect.com/science/article/pii/S0953620513009102es
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivs 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPlasmapheresis
dc.subjectAcute pancreatitis
dc.subjectHypertriglyceridemic pancreatitis
dc.subjectSevere hypertriglyceridemia
dc.subjectPlasmaféresis
dc.subjectPancreatitis
dc.subjectHiperlipidemias
dc.subjectEnfermedad aguda
dc.subjectÍndice de severidad de la enfermedad
dc.subjectResultado del tratamiento
dc.subject.meshPlasmapheresis
dc.subject.meshHyperlipidemias
dc.subject.meshPancreatitis
dc.subject.meshAcute Disease
dc.subject.meshSeverity of Illness Index
dc.subject.meshTreatment Outcome
dc.subject.meshHumans
dc.titlePlasmapheresis as treatment for hyperlipidemic pancreatitis.
dc.typeresearch article
dc.type.hasVersionSMUR
dspace.entity.typePublication
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files